FiercePharma20h
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...
Graphic1d
Energy sector debate heats up — Jinapor’s ECG privatisation plans faces Union backlash
John Jinapor, who was Co-chair of the Akufo-Addo-Mahama transition team's sub-committee on Energy and Natural Resources, ...
Acadia Pharmaceuticals: Positive Sales Projections Amidst Pipeline Uncertainty
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...
Zacks.com on MSN1d
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...
Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030
Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.
Amgen’s Strategic Shift and Strong Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...
Macy’s Stock Falls as Holiday Sales Update Disappoints. What’s Worrying Wall Street.
The company provided investors with an update ahead of its fireside chat at the ICR Conference, scheduled for Tuesday morning. It will report full results for the quarter in early March.